At present we accept the following cards: Visa, Visa Electron, Maestro, Mastercard, Switch and Solo.
Метки:
Zimulti
Посмотрите также
- Zimulti Acomplia Report Covers FDA Panel Meeting on Diet Pill Rimonabant
The make-or-break FDA advisory panel meeting on diet drug rimonabant ( Acomplia (rimonabant) ) will be the subject of team coverage on June 13th by staff of the Zimulti Acomplia , leading independent source of news about rimonabant.
The day-long meeting, which will air concerns raised about “rimonabant [...]
- Zimulti Acomplia News About Rimonabant Sales of Acomplia Lag, But Sanofi Still Has High Hopes for Rimonabant
With sales of Acomplia (rimonabant) lagging in the several dozen countries where it is on the market, Sanofi-Aventis executives had little to say about their pioneering obesity treatment in a report to analysts on Feb. 12th. But that hardly means they have given up on the CB-1 receptor antagonist. [...]
- Zimulti Acomplia News — Oct. 2007 — News About Rimonabant
Diet Drug Taranabant Yields Encouraging Results With ‘Generally Mild’ Side-Effects Taranabant, which a year from now may have surged past (Acomplia) rimonabant as the world’s most eagerly awaited diet drug, made a low-key debut Oct. 24th when researchers reported that participants in a clinical trial achieved encouraging weight loss with [...]
- Will We See FDA Movement on Acomplia in January?
In the absence of any real news on where the FDA decision process stands on the new anti-obesity drug Acomplia (rimonabant), speculation has begun to focus on whether a key agency rimonabant advisory committee will consider the merits of the drug at a January meeting.
The FDA’s Endocrinologic [...]
- Will FDA Leadership Change Impact Approval of Acomplia?
The surprise resignation of embattled U.S. Food and Drug Administration Commissioner Lester M. Crawford injects a new element of uncertainty into the regulatory approval process for the anti-obesity drug Acomplia (rimonabant) .
Crawford, 67, resigned Sept. 23 only two months after being confirmed by the U.S. Senate, leaving behind an [...]
- Will FDA Advisory Committee Consider Acomplia, and When?
The U.S. Food and Drug Administration advisory committee that is expected to weigh in on the new anti-obesity drug Acomplia (rimonabent) prior to an FDA decision on approval apparently does not intend to take up the drug at its December meeting.
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee, which reviews and [...]
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
Comments
Еще нет комментариев.
Извините, комментирование на данный момент закрыто.